Drug
Mp0317
Mp0317: highest development phase Phase 1, developed by Molecular Partners. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Molecular Partners
Trials
| Drug | Phase | Indication |
|---|---|---|
| MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen) NCT05098405 | Phase 1 | Advanced Malignant Solid Tumor |
Latest
No recent events.
Follow Mp0317 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.